Nocturia News and Research

RSS

Men with severe sleep problems face increase risk of prostate cancer

Men who reported sleep problems, including difficulty falling asleep and staying asleep, had up to a twofold increased risk for prostate cancer, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

7 May 2013

First patient dosed in second Phase 2 study with LiRIS for treatment of Interstitial Cystitis

TARIS Biomedical, a specialty pharmaceutical company developing innovative, targeted therapies to treat bladder diseases with high unmet medical need, announced today that it has dosed the first patient in its second Phase 2 clinical study with LiRIS, its novel product candidate, in patients with Interstitial Cystitis.

3 Apr 2013

Mirabegron reduces frequency of incontinence episodes in phase III trial

In a new phase III trial mirabegron, a β3-adrenoceptor agonist, given once daily for 12 weeks, reduced the frequency of incontinence episodes and number of daily urinations, and improved urgency and nocturia in adults with overactive bladder compared to those in a placebo group.

5 Mar 2013

Tolvaptan improves kidney health in polycystic kidney disease

A vasopressin V2-receptor blocker slows the increase in total kidney volume and decline in kidney function in patients with autosomal dominant polycystic kidney disease, report US researchers.

12 Nov 2012

Antimuscarinics only moderately effective for overactive bladder

A comprehensive review of oral antimuscarinics for the treatment of overactive bladder concludes that the efficacy of treatment is, at best, moderate.

17 Sep 2012

Link between sleep apnoea and overactive bladder syndrome in women

Sleep apnoea in women has been linked to overactive bladder syndrome in a new study. The research, presented at the European Respiratory Society's Annual Congress in Vienna, has provided new evidence suggesting a connection between the two conditions.

3 Sep 2012

Symptom relief at the core of prostate patient management

More focus should be placed on relieving the most bothersome or “core” symptom for patients with benign prostatic hyperplasia, report Korean researchers.

11 Jul 2012

Botulinum toxin effective in treating OAB among women

The biggest study into the treatment of urinary incontinence with botulinum toxin (trade name Botox) has demonstrated that it is effective in treating overactive bladder (OAB) - a debilitating common condition which can affect up to 20% of people over the age of 40.

12 Mar 2012

European Urology to launch two new Resource Centres

European Urology, the official peer-reviewed journal of the EAU, is to launch two new Resource Centres that can be accessed from www.europeanurology.com. Both resource centres aim to provide information around a specific topic in urology.

24 Feb 2012

More of saw palmetto does not reduce urinary symptoms related to BPH

Men with urinary problems related to an enlarged prostate who received increasing doses of the fruit extract saw palmetto did not experience a reduction in these symptoms compared to men who received placebo, according to a study in the September 28 issue of JAMA.

28 Sep 2011

Urologic Nursing publishes NAFC nocturia research in middle-aged American women

Research by the National Association For Continence about nocturia in middle-aged American women appears in the current issue of Urologic Nursing, the official journal of the Society of Urologic Nurses and Associates.

22 Apr 2011

Genetic factors can explain people's susceptibility to urinary incontinence

Much of the risk of developing incontinence before middle age is determined by our genes. Genetic factors can explain half of people's susceptibility to urinary incontinence, a study of twins at the University of Gothenburg and Karolinska Institutet reveals.

5 Apr 2011

Patients with BPE may have Obstructive Sleep Apnea

Ben-Gurion University of the Negev researchers have shown that a significant number of patients with benign prostate enlargement may have Obstructive Sleep Apnea, which may be the reason for their night awakenings and urination.

16 Mar 2011

New study: Circadian system may contribute to daily pattern of vasovagal syncope

Fainting, or syncope, is quite common. About 50% of people will experience fainting at some point during their lifetime. The most common type of fainting is vasovagal syncope that is caused by a sudden drop in blood pressure resulting in reduced blood flow to the brain.

8 Mar 2011

XYTOS shares cancer patient treatment results

XYTOS Shares Patient Results.

28 Jan 2011

Allergan second-quarter diluted EPS increases to $0.78

Allergan, Inc. today announced operating results for the quarter ended June 30, 2010. Allergan also announced that its Board of Directors has declared a second quarter dividend of $0.05 per share, payable on September 7, 2010 to stockholders of record on August 17, 2010.

3 Aug 2010

SWHR hosts briefing on urinary incontinence, overactive bladder

The Society for Women's Health Research (SWHR) hosted the Capitol Hill briefing, The Bladder Matters: What Women Need to Know on Thursday, July 15, which highlighted startling statistics and an insightful patient perspective. Featuring noted researchers, physicians, Hill staff, and a UI-afflicted patient, the aim of this widely attended briefing was to detail current research on urinary incontinence (UI) and present future outlooks.

22 Jul 2010

SPET-085 is effective in blocking critical enzyme that leads to BPH: Study

A new study, published in the July issue of Advances in Therapy, revealed that a novel saw palmetto extract, SPET-085, is as effective as finasteride, the standard prescription drug therapy, in blocking the critical enzyme that leads to benign prostatic hyperplasia.

13 Jul 2010

Nymox reports positive new results from pooled analysis of NX-1207 clinical trials for BPH

Nymox Pharmaceutical Corporation reported today positive new results from pooled analysis of completed clinical trials of NX-1207, the Company's investigational drug for BPH. The trial data shows that patients receiving NX-1207 recorded significant quantitative improvement in the important symptom of urgent need to urinate.

8 Jul 2010

CPEX Pharmaceuticals reports record quarterly royalty revenues from Testim sales

CPEX Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2010. For the quarter CPEX reported revenues of $5.3 million and a net loss of $940,000.

5 May 2010